We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
State attorneys general have refused to grant antitrust clearance for sanofi-aventis and Bristol-Myers Squibb (BMS) to pay Apotex to delay market entry of a generic version of the blood thinner Plavix.
The FBI seized documents from the New York headquarters of Bristol-Myers Squibb (BMS) July 27, the day after BMS said it found out the Department of Justice had launched a criminal investigation into a patent settlement between BMS, sanofi-aventis and Apotex.
The FTC is trying to bring a case that will force the Supreme Court to address the issue of "reverse payment" settlements between brand and generic drugmakers, FTC Commissioner Jon Leibowitz said at a hearing on Capitol Hill July 20.
Barr Laboratories is moving ahead with its plans to purchase Croatian generic firm Pliva, announcing July 24 it is confident it can meet the FTC’s conditions for the approving the transaction.
The FTC is trying to bring a case that will split circuit court opinion and force the Supreme Court to address the issue of “reverse payment” settlements between brand and generic drugmakers, FTC Commissioner Jon Leibowitz said at a hearing on Capitol Hill July 20.
The Supreme Court has rejected the Federal Trade Commission’s (FTC) appeal to hear a case that could have ended the practice of reverse payments, spurring swift congressional action to outlaw such agreements.
Watson Pharmaceuticals and Andrx have extended their merger deadline an additional two months to address the FTC’s review of the transaction, the companies said.
The FDA’s hold on approving Croatian drugmaker Pliva’s drug applications imposed after the agency cited it for current good manufacturing practice (cGMP) violations has been lifted, the company said.
Though the Supreme Court has rejected the FTC’s appeal to review an antitrust case challenging the practice of reverse payments — brand drugmakers paying generic drugmakers to delay generic competition — a similar case may come up for review that will force the court to revisit the issue, one legal expert told DID.
The Supreme Court has rejected the FTC’s appeal to hear a case that could have ended the practice of reverse payments, spurring swift congressional action to outlaw such agreements.